Related Experiment Video
Updated: Jul 17, 2026

Bronchoalveolar Lavage (BAL) for Research; Obtaining Adequate Sample Yield
Published on: March 24, 2014
An Apparatus to Deliver Mannitol Powder for Bronchial Provocation in Children Under Six Years Old
Patricia Tang1, Sharon S Y Leung1, Eleanor Hor1
11 Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney , Sydney, New South Wales, Australia .
Insights
A new aerosol delivery system enables bronchial provocation testing in young children without special inhalation training. This system reliably disperses mannitol powder for safe and effective testing in children under 6 years old.
Area of Science:
- Pediatric respiratory medicine
- Aerosol science and technology
Background:
- Bronchial provocation testing (BPT) with mannitol is currently not feasible for children under 6 years due to difficulties in generating sufficient inspiratory effort.
- A novel prototype system bypasses the need for inhalation training by using compressed air to disperse mannitol into a holding chamber for tidal breathing.
Purpose of the Study:
- To develop and evaluate a prototype aerosol delivery system for mannitol bronchial provocation testing in young children.
- To ensure the system can deliver consistent and safe doses of mannitol for pediatric BPT.
Main Methods:
- A prototype system utilizing a commercial powder disperser and holding chamber was developed.
- Taguchi experimental design optimized dispersion parameters to achieve a reliable fine particle dose (FPD).
- In vitro testing with a USP throat and next-generation impactor, followed by calculation of the provocative dose (PD15) for children aged 1-6 years.
Main Results:
- The prototype system successfully generated consistent and reproducible fine particle doses (FPDs) of mannitol.
- Reliable FPDs ranged from 0.8 mg to 14 mg.
- Calculated PD15 values for children (1-6 years) ranged from 7.1-30 mg, with generated FPDs below this threshold, indicating safety.
Conclusions:
- A prototype aerosol delivery system has been successfully developed for pediatric bronchial provocation testing.
- The system consistently delivers safe and effective doubling doses of mannitol suitable for children under 6 years.
- This innovation facilitates BPT in a previously untested pediatric age group.
Background:
Currently bronchial provocation testing (BPT) using mannitol powder cannot be performed in children under 6 years. A primary reason is it is challenging for children at this age to generate a consistent inspiratory effort to inhale mannitol efficiently from a dry powder inhaler. A prototype system, which does not require any inhalation training from the pediatric subject, is reported here. It uses an external source of compressed air to disperse mannitol powder into a commercial holding chamber. Then the subject uses tidal breathing to inhale the aerosol.
Method:
The setup consists of a commercially available powder disperser and Volumatic™ holding chamber. Taguchi experimental design was used to identify the effect of dispersion parameters (flow rate of compressed air, time compressed air is applied, mass of powder, and the time between dispersion and inhalation) on the fine particle dose (FPD). The prototype was tested in vitro using a USP throat connected to a next generation impactor. The aerosols from the holding chamber were drawn at 10 L/min. A scaling factor for estimating the provoking dose to induce a 15% reduction in forced expiratory volume in 1 second (FEV1) (PD15) was calculated using anatomical dimensions of the human respiratory tract at various ages combined with known dosing values from the adult BPT.
Results:
Consistent and doubling FPDs were successfully generated based on the Taguchi experimental design. The FPD was reliable over a range of 0.8 (±0.09) mg to 14 (±0.94) mg. The calculated PD15 for children aged 1-6 years ranged from 7.1-30 mg. The FPDs generated from the proposed set up are lower than the calculated PD15 and therefore are not expected to cause sudden bronchoconstriction.
Conclusion:
A prototype aerosol delivery system has been developed that is consistently able to deliver doubling doses suitable for bronchial provocation testing in young children.
Related Concept Videos
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Inhaled Medications

